NASDAQ:KMDA Kamada (KMDA) Stock Price, News & Analysis $7.05 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$7.04 -0.01 (-0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kamada Stock (NASDAQ:KMDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kamada alerts:Sign Up Key Stats Today's Range$6.97▼$7.0750-Day Range$6.85▼$8.0252-Week Range$5.17▼$9.15Volume43,571 shsAverage Volume130,351 shsMarket Capitalization$405.45 millionP/E Ratio20.74Dividend YieldN/APrice Target$13.00Consensus RatingModerate Buy Company Overview Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. Read More Kamada Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreKMDA MarketRank™: Kamada scored higher than 95% of companies evaluated by MarketBeat, and ranked 66th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingKamada has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKamada has received no research coverage in the past 90 days.Read more about Kamada's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth39.13% Earnings GrowthEarnings for Kamada are expected to grow by 39.13% in the coming year, from $0.23 to $0.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kamada is 20.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Kamada is 20.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.38.Price to Earnings Growth RatioKamada has a PEG Ratio of 0.76. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioKamada has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kamada's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.15% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently decreased by 48.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKamada does not currently pay a dividend.Dividend GrowthKamada does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.15% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently decreased by 48.59%, indicating that investor sentiment is improving significantly. News and Social Media4.1 / 5News Sentiment1.36 News SentimentKamada has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kamada this week, compared to 2 articles on an average week.Search Interest4 people have searched for KMDA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Kamada to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kamada insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.38% of the stock of Kamada is held by institutions.Read more about Kamada's insider trading history. Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KMDA Stock News Headlines3 Reasons Growth Investors Will Love Kamada (KMDA)August 19, 2025 | msn.comKamada Ltd. (NASDAQ:KMDA) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 26 at 2:00 AM | InvestorPlace (Ad)What Makes Kamada (KMDA) a New Buy StockAugust 14, 2025 | msn.comKamada Ltd (KMDA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Increased ...August 14, 2025 | finance.yahoo.comKamada (KMDA) Reports Q2 Earnings: What Key Metrics Have to SayAugust 14, 2025 | msn.comKamada Q2 2025 Earnings PreviewAugust 12, 2025 | msn.com3KMDA : An Overview of Kamada's EarningsAugust 12, 2025 | benzinga.comSee More Headlines KMDA Stock Analysis - Frequently Asked Questions How have KMDA shares performed this year? Kamada's stock was trading at $6.09 at the beginning of 2025. Since then, KMDA stock has increased by 15.8% and is now trading at $7.05. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) announced its quarterly earnings data on Wednesday, August, 13th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.04. The biotechnology company had revenue of $44.75 million for the quarter, compared to analyst estimates of $158.59 million. Kamada had a trailing twelve-month return on equity of 7.41% and a net margin of 11.22%. Read the conference call transcript. Who are Kamada's major shareholders? Top institutional investors of Kamada include Acadian Asset Management LLC (0.46%), ARK Investment Management LLC (0.44%), Marshall Wace LLP (0.27%) and Huntleigh Advisors Inc. (0.24%). How do I buy shares of Kamada? Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), ASML (ASML) and Oracle (ORCL). Company Calendar Last Earnings8/13/2025Today8/26/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KMDA CIK1567529 Webwww.kamada.com Phone(728) 940-6472Fax972-8940-6473Employees360Year FoundedN/APrice Target and Rating Average Price Target for Kamada$13.00 High Price Target$15.00 Low Price Target$11.00 Potential Upside/Downside+84.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.34 Trailing P/E Ratio20.72 Forward P/E Ratio30.63 P/E Growth0.76Net Income$14.46 million Net Margins11.22% Pretax Margin11.07% Return on Equity7.41% Return on Assets5.18% Debt Debt-to-Equity RatioN/A Current Ratio4.00 Quick Ratio2.21 Sales & Book Value Annual Sales$160.95 million Price / Sales2.52 Cash Flow$0.48 per share Price / Cash Flow14.60 Book Value$4.51 per share Price / Book1.56Miscellaneous Outstanding Shares57,510,000Free Float36,746,000Market Cap$405.16 million OptionableOptionable Beta0.93 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:KMDA) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.